H
Hans Prenen
Researcher at University of Antwerp
Publications - 204
Citations - 9145
Hans Prenen is an academic researcher from University of Antwerp. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 41, co-authored 163 publications receiving 7293 citations. Previous affiliations of Hans Prenen include Monash Medical Centre & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem,Josep Tabernero,Radek Lakomy,Hans Prenen,Jana Prausová,Teresa Macarulla,Paul Ruff,Guy van Hazel,Vladimir Moiseyenko,David R. Ferry,Joseph McKendrick,J. Polikoff,Alexia Tellier,Remi Castan,Carmen J. Allegra +14 more
TL;DR: Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities.
Journal ArticleDOI
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer,Eric Van Cutsem,Alfredo Falcone,Takayuki Yoshino,Rocio Garcia-Carbonero,Nobuyuki Mizunuma,Kentaro Yamazaki,Yasuhiro Shimada,Josep Tabernero,Yoshito Komatsu,Alberto Sobrero,Eveline Boucher,Marc Peeters,Ben Tran,Heinz-Josef Lenz,Alberto Zaniboni,Howard S. Hochster,James M. Cleary,Hans Prenen,Fabio Benedetti,Hirokazu Mizuguchi,Lukas Makris,Masanobu Ito,Atsushi Ohtsu +23 more
TL;DR: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival, and this phase 3 trial was the first to report this result.
Journal ArticleDOI
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
Maria Debiec-Rychter,Jan Cools,Herlinde Dumez,Raf Sciot,Michel Stul,Nicole Mentens,Hilde Vranckx,Bartosz Wasag,Bartosz Wasag,Hans Prenen,Johannes Roesel,Anne Hagemeijer,Allan T. van Oosterom,Peter Marynen +13 more
TL;DR: This study shows the high frequency of KIT/PDGFRA kinase domain mutations in patients with secondary resistance and defines genomic amplification of Kit / PDGFRA as an alternative cause of resistance to the drug.
Journal ArticleDOI
MET is required for the recruitment of anti-tumoural neutrophils
Veronica Finisguerra,Giusy Di Conza,Mario Di Matteo,Jens Serneels,Sandra Costa,A. A. Roger Thompson,Els Wauters,Sarah R. Walmsley,Sarah R. Walmsley,Hans Prenen,Zvi Granot,Andrea Casazza,Massimiliano Mazzone +12 more
TL;DR: It is shown that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor (HGF), and it is proved that the therapeutic benefit of MET targeting in cancer cells is partly countered by the pro-tumoural effect arising from MET blockade in neutrophils.
Journal ArticleDOI
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis
Mathias Wenes,Min Shang,Mario Di Matteo,Jermaine Goveia,Rosa Martín-Pérez,Jens Serneels,Hans Prenen,Bart Ghesquière,Peter Carmeliet,Massimiliano Mazzone +9 more
TL;DR: It is proved that the anti-tumor effect of mTOR inhibitors is partly countered by the deleterious outcome of these drugs on TAMs, providing a functional link between TAM metabolism and tumor angiogenesis.